Investor

Paul Grand, CEO of MedTech Innovator, discusses how the accelerator embraces high-risk, high-reward technologies and steers them to market with industry expertise.

The investment will accelerate Nexus IT’s U.S. expansion and support acquisitions of culturally aligned MSPs in healthcare and other regulated industries.

The two organizations will collaborate to accelerate the company's growth and enhance proactive care and management of chronic diseases.

Kidd's company will use 1,000 Bitcoin and additional cash to acquire the interest, and the former Ripple chief risk officer will become CEO and chairman of the board.

The company is offering 7.9 million of its common stock at an initial price of $19 per share, with shares trading under the ticker symbol OMDA.

Morgan Cheatham, partner and head of healthcare and life sciences at Breyer Capital, provides highlights of the venture capital firm's strategy when funding emerging technologies and the risks associated with backing these innovations.

Alexandre Momeni, a partner at General Catalyst, describes how the VC firm funds visionary founders building frontier technologies while balancing high-risk bets with responsible innovation and strategic portfolio construction.

The company will grow its clinical team and expand its offerings across GI partner clinics representing 700 physicians, after an 800% rise in patient volume.

Jayme Strauss, chief commercial and clinical officer at Precision Neuroscience, joined MobiHealthNews to discuss the company's brain-computer interface aimed at allowing individuals to control digital devices using their thoughts.

The company will use the funds to support a 510(k) submission to the FDA for its Flexi-Port SLF-TANL for oncology patients.